What Does Servier's $2.5 Billion Acquisition Mean for Day One Biopharmaceuticals

Related Articles

What Just Happened with Day One Biopharmaceuticals and Servier

6 months ago

Why Did Servier Pay a 68% Premium for Day One Biopharmaceuticals

6 months ago

What's Driving Day One's Recent Surge? The Servier Acquisition Explained.

6 months ago

Is Capital One's Bold Acquisition Strategy Paying Off

6 months ago

Category

You may also like

Stock News•3 weeks ago

Edgewise Therapeutics: The Servier Deal Creates A Self-Funded Cardiovascular Platform

Edgewise Therapeutics raised ~$1.55B from selling sevasemten to Servier, extending its cash runway into the early 2030s. The deal self-funds late-stage development of EDG-7500, which showed robust Pha...

EWTX

Share

Stock News•1 months ago

Tempus AI Makes Billion-Dollar Bet on the Future of Cancer Monitoring

Tempus AI agreed to acquire Personalis for ~$1B, aiming to advance cancer monitoring via enhanced minimal residual disease capabilities.

TEM

Share

News•2 months ago

Drugmaker Ipsen Sees More Deals Coming to Continue Buying Spree

Ipsen signaled more acquisitions are coming after this week's two deals, citing portfolio gaps and sufficient financial resources per its chief business officer.

Share